Market Overview - Major indices showed declines: Shanghai Composite Index (-0.64%), Shenzhen Component Index (-1.37%), ChiNext Index (-1.96%), North Star 50 (-2.50%), and Sci-Tech Innovation 50 (-2.80%) [1] - TMT sector led the gains with SW Portal (+6.79%), SW Marketing Agency (+2.49%), and SW Gaming III (+0.40%) [1] - TMT sector faced losses with SW Military Electronics III (-5.41%), SW Communication Terminals and Accessories (-5.34%), and SW Communication Cables and Accessories (-5.20%) [1] Domestic News - XREAL announced a strategic partnership with ASUS ROG to launch the ROG XREAL R1 AR glasses, featuring micro OLED technology with a resolution of 1920 x 1080 and a virtual screen equivalent to 171 inches at 4 meters [2] - Jiangbolong reported that its self-developed UFS4.1 product outperforms market counterparts in process, read/write speed, and stability, gaining recognition from major clients [2] - Yongxi Electronics plans to invest 2.1 billion yuan in a packaging base in Malaysia, focusing on system-level packaging products for AIoT and power modules [2] - Sanan Optoelectronics disclosed that its SiC MOSFET products have begun bulk supply to leading global power manufacturers, targeting data centers and AI servers [2] Overseas News - SK Hynix is investing in its advanced packaging plant P&T7 to meet global AI storage demand, with the plant expected to play a crucial role in commercializing DRAM as HBM [3] - A collaboration between the University of Cambridge and a German research team has led to the successful development of stable and high-performance cubic InGaN materials for red Micro-LED devices [3] - Counterpoint Research forecasts a 2% year-on-year growth in global smartphone shipments in 2025, driven by high-end demand and emerging market growth, with Apple leading the market at a 20% share [3] - The Indian Space Research Organization (ISRO) faced a setback with the PSLV-C62 rocket losing all 16 satellites during its third phase of flight [3] AI News - Apple and Google have announced a multi-year partnership to develop the next generation of Apple Foundation Models based on Google's Gemini model and cloud technology [4] - Zhipu AI and Didi Chuxing have formed a strategic partnership focusing on the development of intelligent agents for transportation scenarios [4] - Tencent Research Institute and Midjourney have launched the Niji v7 anime-specific model, enhancing details and stability for anime-style creations [4] - Nvidia and Eli Lilly are investing $1 billion to establish an AI lab aimed at accelerating drug discovery and personalized treatment [4] Industry Tracking - The FCC has approved SpaceX to launch an additional 7,500 second-generation Starlink satellites, bringing the total approved to 15,000 [5] - The Eighth Research Institute of China Shipbuilding Group has developed a low-vibration helium re-liquefaction system for high-precision instruments [5] - The National Medical Products Administration of China plans to establish standards for medical devices using brain-computer interface technology [5] - LimX Dynamics has released a new embodied intelligent system that allows for dynamic task adjustments during operation [5] Storage Market - The average price of DDR5 16G (2G×8) 4800/5600 DRAM is reported at $33.563, with a 3.27% increase [6] - The average price of DDR4 16Gb (2G×8) 3200 DRAM is reported at $73.500, with a 2.80% increase [6] Semiconductor Material Prices - The average price for 4N zinc oxide powder is reported at 1,465 yuan/kg, with a daily change of 20 yuan [7] - The average price for 5N high-purity zinc is reported at 6,300 yuan/kg, with no daily change [7]

Core Viewpoint - The company is currently not involved in the brain-computer interface sector but will closely monitor developments in this industry [1] Group 1: AI Technology in Drug Development - The company utilizes AI technology in its innovative drug research, specifically in AIDD (Artificial Intelligence Drug Discovery) and CADD (Computer-Aided Drug Design) [1] - The company has developed its own AI platform, known as the Smart Drug AI platform, which can be applied to toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Organoid Platform and Drug Development Services - The company's organoid platform provides drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1] - This platform aims to enhance the precision and efficiency of drug development processes [1]

Core Insights - Shanghai is emerging as a leading international science and technology innovation center, competing with cities like New York, San Francisco, Paris, Tokyo, and London [1][6][12] - Recent research breakthroughs, such as the decoding of the symbiotic pairing code between leguminous plants and rhizobia, highlight the city's scientific advancements [3][4] - The Shanghai government is significantly increasing its investment in scientific research, with an average annual growth rate of over 20% in fiscal science and technology spending from 2022 to 2025 [4][10] Investment and Research Growth - By 2025, Shanghai scientists are projected to publish 181 top journal papers, accounting for 30.6% of the national total, a 14.6% increase from 2024 [4] - The city's R&D expenditure is expected to reach 4.5% of its GDP during the "14th Five-Year Plan" period, with a total increase of 85% in basic research funding [4][10] - Shanghai's technology activity output score is 99.82, maintaining the top position nationally, with significant growth in technology international income and patent registrations [7][8] Innovation Ecosystem - The integration of technology innovation and industrial innovation is a key focus, with efforts to enhance the city's innovation capabilities and high-end industry leadership [8][10] - Shanghai's technology transfer reforms have allowed universities to transfer rights of research outcomes to teams, resulting in a significant increase in technology contract amounts [11][12] - The city aims to foster a world-class technology innovation source by collaborating with neighboring regions, enhancing its overall innovation ecosystem [13]

Group 1 - Strong Brain Technology has submitted a confidential IPO application to the Hong Kong Stock Exchange, with expectations that its listing is only a matter of time [2] - The company recently completed approximately 2 billion yuan in Pre-IPO financing, achieving a post-investment valuation of over 1.3 billion USD [2] - The global brain-computer interface (BCI) market is experiencing significant growth, with a compound annual growth rate (CAGR) of over 13% from 2019 to 2023, and is projected to reach 7.63 billion USD by 2029 [4] Group 2 - The funds raised from the recent financing will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling [3] - Strong Brain Technology aims to help 1 million physically disabled individuals regain daily life through neural-controlled prosthetics and improve the conditions of 10 million patients suffering from brain-related disorders [3] - The company differentiates itself from competitors like Neuralink by focusing on non-invasive solutions and developing super sensors to detect human neural signals [4] Group 3 - The Chinese government has included brain-computer interfaces in its national strategic planning, indicating a shift from laboratory research to a national priority [4] - The stock market has reacted to the BCI concept, with companies like Innovation Medical and Rock Mountain Technology experiencing consecutive trading gains [4] - Recent inquiries from the Shanghai Stock Exchange regarding partnerships in the BCI space highlight the regulatory scrutiny and market interest surrounding this technology [5]

Core Viewpoint - The company is actively monitoring the application and development of cutting-edge technologies, including brain-computer interfaces, in the healthcare sector, and is committed to a cautious and pragmatic layout based on clinical value and long-term strategic direction [1] Group 1: Company Developments - The company has established a comprehensive management plan for Parkinson's disease treatment using brain-computer interfaces, covering preoperative screening, intraoperative implementation, postoperative monitoring, and rehabilitation [1] - The company's affiliated Yuncheng Hospital has successfully completed over 20 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] Group 2: Technological Innovations - The company-managed Shanghai Yongci Rehabilitation Hospital has collaborated with Fourier to create a leading domestic rehabilitation robot IoT port [1] - The rehabilitation robot, as the core device of the IoT port, offers highly personalized rehabilitation services, enhances rehabilitation efficiency, and effectively optimizes the allocation of human resources for rehabilitation therapists [1] Group 3: Commitment to Transparency - The company adheres to an open and win-win ecological philosophy and will fulfill its information disclosure obligations in a timely manner according to legal regulations and supervisory requirements for any significant developments [1]

Core Viewpoint - Nanjing Panda (600775) maintains its focus on three main business areas: smart transportation and safe city, industrial internet and intelligent manufacturing, and green service-oriented electronic manufacturing, with no changes reported [1] Business Focus - The company has not developed any mature products related to brain-computer interfaces as of now [1] - There has been no revenue generated from brain-computer interface-related sales [1]

Core Viewpoint - The article discusses the recent fluctuations in the A-share market, highlighting the mixed sentiment among investors and the potential for continued volatility leading up to the Two Sessions in March [1][3]. Market Overview - On January 13, the three major indices in the A-share market collectively declined, with the Shanghai Composite Index down 0.64%, the Shenzhen Component down 1.37%, and the ChiNext down 1.96% [8]. - The total trading volume reached 36,991.09 billion yuan, an increase of 541.38 billion yuan from the previous day, setting a new historical record [8]. - Over 3,700 stocks in the market experienced declines, with 77 stocks hitting the daily limit up [8]. Sector Performance - The medical services sector showed strength, with several stocks, including Nuo Si Ge and Pu Rui Si, hitting the daily limit up [8]. - The AI application sector experienced volatility, with stocks like Tianlong Group and Di'an Diagnosis also reaching the daily limit up [8]. - The commercial aerospace sector faced adjustments, with several stocks dropping over 10% [8]. Investment Trends - According to CITIC, the current market sentiment is high, but there are no signs of weakening indicators yet. The short-term outlook suggests a continued rotation among themes and small-cap stocks until the Two Sessions [3]. - The article notes that the expected incremental capital for 2026 is projected at 30,378.13 billion yuan, with various sources contributing to this growth, including household deposits and institutional asset reallocation [4]. Company Highlights - Three Transform Technology has been involved in providing gas turbine transformers for the U.S. Musk xAI supercomputing data center, indicating a growing demand in the energy sector [6]. - TCL Technology expects a net profit of 4.21 billion to 4.55 billion yuan for 2025, representing a year-on-year growth of 169% to 191% [17]. - Dazhu CNC anticipates a net profit of 785 million to 885 million yuan for 2025, driven by increased demand for AI server components [17]. Regulatory and Policy Updates - The Ministry of Commerce announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective January 14, 2026, for a period of five years [13]. - The article mentions a strategic partnership between EndoQuest Robotics and NVIDIA to enhance surgical robotics with high-performance computing [14]. Capital Flow Insights - The net outflow of main funds reached 117.06 billion yuan, with the electronic sector experiencing the largest outflow [20]. - The article highlights the net inflow of funds into sectors such as media, pharmaceuticals, and non-ferrous metals, while sectors like electronics and defense saw significant outflows [20].

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Market Analysis - The A-share market experienced a correction, ending a 17-day consecutive rise, with the Shanghai Composite Index closing at 4138.76 points, down 0.64% [3] - The Shenzhen Composite Index fell by 1.37% to 14169.40 points, while the ChiNext Index dropped 1.96% to 3321.89 points, indicating a broad market adjustment [3] - Despite the market correction, trading volume remained high at 3.7 trillion yuan, reflecting sustained trading activity [8] Sector Performance - A shift in market style was observed, with funds moving from high-position themes to defensive sectors, such as oil and petrochemicals, pharmaceuticals, and non-ferrous metals, which saw gains [6] - The commercial aerospace sector faced significant declines, with a drop of 6.15%, marking the largest single-day decline since the recent rally began [6] - The lithium carbonate futures surged, reaching a new high of 174,060 yuan/ton, driven by strong demand and supply constraints [12] Bond Market - The government bond futures market showed a recovery, with the 30-year contract (TL2603) rising by 0.28% to close at 111.35 yuan [12] - The central bank's net injection of 342.4 billion yuan contributed to a generally loose liquidity environment, despite short-term interest rates rising [12] - The bond market sentiment improved, indicating a potential shift towards long-term bonds as the new year begins [18] Commodity Market - The commodity market displayed significant divergence, with non-ferrous metals maintaining a leading position, while other sectors faced pressure [10] - The South China commodity index closed at 2736.38 points, down 0.24%, with lithium carbonate, silver, and tin leading the gains [10] - Geopolitical uncertainties in the Middle East have contributed to rising oil prices, with potential implications for global oil supply [13] Investment Themes - Key investment themes include AI applications, commercial aerospace, nuclear fusion, quantum technology, brain-computer interfaces, robotics, and consumer sectors, all supported by policy initiatives and technological advancements [14] - The insurance and brokerage sectors are expected to benefit from high trading volumes in the A-share market, with potential changes in trading regulations being monitored [14] - The precious metals sector is anticipated to perform well due to central bank purchases and expectations of further interest rate cuts by the Federal Reserve [14]

证券日报网讯 1月13日，首都在线在互动平台回答投资者提问时表示，脑机接口作为前沿科技领域，其 技术研发与商业化落地高度依赖底层云计算资源的强力支撑。公司深耕云计算领域多年，凭借高性能、 弹性可扩展的算力资源，可高效支撑脑机接口实验产生的海量多模态信号的实时解码分析，为合作方的 模型训练与算法优化提供强劲算力支持；同时，依托安全可靠的云存储与数据管理能力，保障实验数据 全生命周期的安全传输与高效管理。 （文章来源：证券日报） ...